- Company Introduction
- A bio company owning antibody fragment-based technology and development innovative biologics
- Signed the agreement on joint R&D with Celros Biotech Co., Ltd. For double antibody development
- Acquired an international patent (Canada) on SAFA technology
- Dec. Signed the agreement of IPO lead management with NH Investment Securities Co., Ltd.
Dec. Signed the agreement of CDMO with Samsung Biologics Co., Ltd.
- July Approval of SAFA tropin IND filing for technology transfer for Ahn-gook Pharmacy Co., Ltd.
- Acquired an international patent (Japan) on SAFA technology
- Investment agreement from seven investors for Series A (KRW 7.5 billion)
- Acquired an international patent (USA) on SAFA technology
- Investment agreement from four investors for Pre-Series A (KRW 3.0 billion)
- Established R&D Center at Chuncheon Bio Industry Promotion Agency
- SEED _ Investment agreement from two investors for SEED (KRW 2.3 billion)
SAFA technology Acquired an international patent (Korea) on SAFA technology
- Signed the agreement for technology transfer for Ahn-gook Pharmacy Co., Ltd. on long-acting type hGH and G-CSF
- Acquired the certification of Venture Company
- Established April Bio Co., Ltd.